Is The Downturn A ‘Darwinian Moment’ For Biotech? The View From The Frontline

Cutbacks And Threat Of Closure Hitting Small To Medium Biotechs

 
• By Andrew McConaghie
  
NASDAQ
Don't cross over: this year has seen negative sentiment hitting biotech valuations, with very limited public market raises or IPOs. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip